To test whether activation of RORα could promote DM bone regeneration, we established a calvarial defect model in type 2 DM rats and SR1078, a selective agonist of RORα, was administered to activate RORα driven transcription (Figure 1A). Here, RORA is linked to diabetes mellitus.